Contact us
If you'd like to get in touch, please contact us by phone or email.
Phone: 0400 450 240
Email: vtg@telethonkids.org.au
Team
Vaccine Trials Group projects
Past projects
News
Superbugs on 7 News
Protecting children against food allergies
What is pneumococcal disease?
Reports and Findings
Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers
The bacille Calmette-Guérin (BCG) vaccine has immunomodulatory "off-target" effects that have been hypothesized to protect against coronavirus disease 2019.
Published research Immunisation Influenza Infectious Diseases Vaccine Trials Group Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases Subsite: Walyan COVID-19 Immunology and Breast Feeding Strep A & ARF TherapeuticsA phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
To evaluate the safety and immunogenicity of V114 [15-valent pneumococcal conjugate vaccine (PCV) containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, 22F, 23F, 33F], followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks later, in children with HIV.
Published research Immunisation Infectious Diseases Vaccine Trials Group Subsite: Wesfarmers Centre of Vaccines and Infectious DiseasesA Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)
Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and immunogenicity of V114 (VAXNEUVANCE; Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA), a 15-valent pneumococcal conjugate vaccine (PCV), when given to allo-HCT recipients.
Published research Immunisation Infectious Diseases Vaccine Trials Group Subsite: Wesfarmers Centre of Vaccines and Infectious DiseasesNirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data
Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season. Previous studies have shown that the nirsevimab binding site is highly conserved. However, investigations of the geotemporal evolution of potential escape variants in recent (ie, 2015–2021) RSV seasons have been minimal.
Published research Infectious Diseases Vaccine Trials Group Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases Respiratory viral infections